(Total Views: 468)
Posted On: 03/10/2018 1:05:17 PM
Post# of 30067
The Door for MANF is Open:
Herantis’s Parkinson’s Therapy Passes Preliminary Trial Safety Evaluation
FEBRUARY 20, 2018
"An independent review board has found Herantis Pharma’s Parkinson’s therapy safe, paving the way for a Phase 1/2 clinical trial in Sweden to continue."
https://parkinsonsnewstoday.com/2018/02/20/he...valuation/
Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson’s Disease
Volume 374, 15 March 2018, Pages 250-263
Highlights:
• CDNF alone had minimal neurorestorative effect in a MFB 6-OHDA lesion model of PD.
• CDNF or STN DBS alone or in combination had minimal effect on dopamine biochemistry.
• CDNF combined to subthalamic nucleus lesion alleviated behavioral defects.
• Researchon NTF and DBS may lead to combined neuroprotection and symptom control.
https://www.sciencedirect.com/science/article...2218300824
Herantis’s Parkinson’s Therapy Passes Preliminary Trial Safety Evaluation
FEBRUARY 20, 2018
"An independent review board has found Herantis Pharma’s Parkinson’s therapy safe, paving the way for a Phase 1/2 clinical trial in Sweden to continue."
https://parkinsonsnewstoday.com/2018/02/20/he...valuation/
Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson’s Disease
Volume 374, 15 March 2018, Pages 250-263
Highlights:
• CDNF alone had minimal neurorestorative effect in a MFB 6-OHDA lesion model of PD.
• CDNF or STN DBS alone or in combination had minimal effect on dopamine biochemistry.
• CDNF combined to subthalamic nucleus lesion alleviated behavioral defects.
• Researchon NTF and DBS may lead to combined neuroprotection and symptom control.
https://www.sciencedirect.com/science/article...2218300824
(6)
(0)
